CD79B and B-cell non-Hodgkin lymphoma: Besides brentuximab vedotin, polatuzumab vedotin, an FDA-approved ADC targeting CD79b for treating B cell lymphoma (17), and enfortumab vedotin, an FDA-approved ADC targeting nectin-4 for treating urothelial cancer (18), also utilize the same linker and MMAE as the payload, demonstrating the clinical safety and efficacy of this approach for ADC development.